Succeeder(SH:688338) Sou Hu Cai Jing·2025-08-04 12:05Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Saikohide, a company specializing in medical devices for thrombosis and hemostasis diagnostics [1][2] - As of August 4, Saikohide's closing price was 27.48 yuan, with a rolling price-to-earnings (PE) ratio of 27.59 times and a total market capitalization of 2.917 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, positioning Saikohide at the 54th rank within the industry [1][2] Group 2 - As of March 31, 2025, Saikohide had 6,725 shareholders, an increase of 1,118 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company's main business includes the research, development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - In the latest quarterly report for Q1 2025, Saikohide reported revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross profit margin of 62.49% [1]